What do we already know about this topic?

• The American Headache Society’s (AHS) position statement recommends migraine patients should experience the failure of two preventative medications before receiving CGRP (Calcitonin Gene-Related Peptide) targeted mAb (monoclonal antibody) treatment. ¹
• The 2018 OVERCOME (ObserVational survey of the Epidemiology, tReatment and Care Of MigrainE) web-based survey provides a US representative sample (n=21,143) of the migraine healthcare landscape.

How was this study conducted?

• A moderate-to-severe disability group (n=5,895) of migraine patients was selected from the OVERCOME survey using MHD (monthly headache days) ≥ 4 and MIDAS (Migraine Disability Assessment) ≥ 11. Subgroups were then created based upon patients being prescribed or recommended 0, 1, or ≥2 medications.²
• Sociodemographic differences and migraine-related factors by the number of recommended migraine prevention medications were analyzed using a t-test (continuous variables) or Chi-square test (categorical variables). ^3-5